Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
John Heymach, MD, PhD
Articles
Zongertinib Shows Benefit Across Subgroups in HER2-Mutated NSCLC: John Heymach, MD, PhD
April 28th 2025Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.
Zongertinib Shows Durable Responses in Previously Treated HER2-Mutated NSCLC: John Heymach, MD, PhD
April 28th 2025John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.
